Clinical Trials Browser

Enrolling by invitation × Myasthenia Gravis × 1 year × Clear all

Myasthenia Gravis

NCT06540144 2026-02-27

An Extension Study Evaluating 6-week Treatment Cycles of Rozanolixizumab in Pediatric Study Participants With Generalized Myasthenia Gravis

Phase 3 Enrolling by invitation

12 enrolled

Myasthenia Gravis

NCT05374590 2026-02-02

ADAPT Jr +

Phase 2/3 Enrolling by invitation

12 enrolled

Myasthenia Gravis

NCT07217509 2025-10-16

PPDTM CorEvitasTM Myasthenia Gravis (MG) Drug Safety and Effectiveness Registry

Enrolling by invitation

1,500 enrolled

Myasthenia Gravis

NCT06605612 2025-09-10

Amyotrophic Lateral Sclerosis, Friedreich Ataxia, Glycogen Storage Disease Type II, Muscular Atrophy, Spinal, Myasthenia Gravis, Myotonic Dystrophy, Neuromuscular Diseases, Hereditary Sensory and Motor Neuropathy, Lambert-Eaton Myasthenic Syndrome, Myositis, Inclusion Body, Guillain-Barre Syndrome, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, Muscular Dystrophy, Facioscapulohumeral

NCT00704626 2025-05-15

SAA

Enrolling by invitation

120 enrolled

Autoimmune Diseases, Multiple Sclerosis, Myasthenia Gravis, Myelitis, Transverse

Clinical Trials

ziMyG+

An Extension Study Evaluating 6-week Treatment Cycles of Rozanolixizumab in Pediatric Study Participants With Generalized Myasthenia Gravis

ADAPT Jr +

PPDTM CorEvitasTM Myasthenia Gravis (MG) Drug Safety and Effectiveness Registry

FBIndex

SAA